Evidence-based review of the WHO 2025 Guidelines for the Clinical Management of Arboviral Diseases
10.3760/cma.j.issn.1674-2397.2025.04.005
- VernacularTitle:2025版《世界卫生组织关于虫媒病毒疾病临床管理指南》的循证探讨
- Author:
Xinyu WANG
1
Author Information
1. 复旦大学附属华山医院感染科 国家传染病医学中心，上海 200040
- Publication Type:Journal Article
- Keywords:
Arboviruses;
Dengue;
Chikungunya;
Zika virus disease;
Yellow fever;
Clinical practice guideline;
Evidence-based medicine
- From:
Chinese Journal of Clinical Infectious Diseases
2025;18(4):285-289
- CountryChina
- Language:Chinese
-
Abstract:
Arboviral diseases transmitted by Aedes mosquitoes-such as dengue，chikungunya，Zika virus disease，and yellow fever pose an increasing public health threat worldwide. Factors including the expanding geographic range of mosquito vectors，globalization，and climate change have contributed to their spread. These diseases often present with similar early clinical features，complicating differential diagnosis and management，especially in resource-limited settings. In 2025，the World Health Organization（WHO）issued its first integrated evidence-based guidelines for the clinical management of these four arboviral diseases. Developed using the Grading of Recommendations，Assessment，Development，and Evaluations（GRADE）approach，the guidelines provide recommendations for both non-severe and severe cases based on a systematic review of current evidence. This article offers a critical interpretation of the guidelines’ background，key recommendations，and supporting evidence，with discussion of their applicability in the Chinese context. Emphasis is placed on the rationale behind recommendations regarding fluid management，symptomatic treatment，corticosteroid use，and platelet transfusion. The article also addresses the global relevance and limitations of the guidelines and underscores the importance of advancing clinical research in China to contribute to worldwide arboviral disease control efforts.
